The capacity of LY-4 to inhibit progression of BrafV600E;Perk+/- melanomas, implies an “addiction” to the remaining Perk allele suggesting a potential therapeutic threshold for Perk inhibition. This evidence concerns the gene EIF2AK3 and melanoma.